NCT01820260 2025-03-13
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
Clinical Trials
9 trialsNCT01922050 2025-03-06
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02100813 2025-03-06
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02120456 2025-03-06
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT01803477 2025-02-24
Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm
LEO Pharma
Phase 1/2 Completed
NCT06712381 2024-12-02
Carac & PDT Combination in the Treatment Of Actinic Keratoses
Skin Laser & Surgery Specialists
Phase 1/2 Completed
NCT03110159 2024-03-15
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
Medical Dermatology Specialists
Phase 1/2 Completed
NCT05164393 2022-01-27
COAKS
Coegin Pharma AB
Phase 1/2 Unknown
NCT02149342 2016-07-11
Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL
Joint Authority for Päijät-Häme Social and Health Care
Phase 1/2 Completed